Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels. The company also markets proprietary respiratory therapies, including over-the-counter inhaled products. Amphastar leverages its in-house drug delivery technologies to support both its own product lines and contract manufacturing services for third-party partners.
In addition to marketed products, Amphastar maintains a pipeline of new drug candidates and device enhancements, including next-generation inhalation systems and branded formulations. The company’s research and development efforts are centered on improving patient access to essential medications while advancing delivery platforms that enhance convenience and dosing precision.
Amphastar primarily serves the U.S. pharmaceutical market, with select international distribution partnerships. Leadership is anchored by Chief Executive Officer Enno Walther, who oversees strategic growth initiatives and manufacturing operations. The company is governed by a board of directors with experience in pharmaceutical development, regulatory affairs and commercial strategy.
AI Generated. May Contain Errors.
Free AMPH Stock Alerts